# The efficacy of a single dose of oral azithromycin in labour to prevent infections in infants and birthing parents in Fiji: secondary outcomes from a randomised controlled trial

**Authors:** Maeve Hume-Nixon, Stephanie Clark, Tupou Ratu, Cattram Nguyen, Eleanor F G Neal, Kathryn Bright, Aneley Getahun Strobel, Emma Watts, John Hart, James J Fong, Eric Rafai, Kelera Sakumeni, Andrew Steer, Ilisapeci Vereti, Fiona Russell

PMC · DOI: 10.1136/bmjgh-2025-019851 · BMJ Global Health · 2026-03-04

## TL;DR

A single dose of azithromycin during labor in Fiji reduced infections in birthing parents but had limited effects on infant infections.

## Contribution

The study shows azithromycin during labor reduces infections in birthing parents up to 12 months postpartum.

## Key findings

- Azithromycin reduced infant infections at 3 months (RR 0.79) but not at later time points.
- Birthing parent infections were significantly reduced up to 6 months postdelivery.
- No effect on antibiotic prescriptions was observed at any time point.

## Abstract

Our Bulabula MaPei trial of azithromycin administered during labour in Fiji found no evidence of a reduction in the primary endpoint of infant skin and soft tissue infections (SSTIs) at 3 months of age. Here, we determine the efficacy of this intervention on several secondary outcomes.

This randomised controlled trial included healthy pregnant adults presenting to hospital in labour. Prior to delivery, participants were randomly assigned a single dose of 2 g of oral azithromycin or placebo that were identical in appearance to mask treatment allocation, in a 1:1 ratio stratified by ethnicity. Cumulative incidence of infections and antibiotic prescription was compared using an intention-to-treat analysis of complete cases. Adverse events described as proportions by group at specified time points.

From June 2019 to January 2022, we enrolled 2110 pregnant people and their infants (n=2122; azithromycin n=1059; placebo n=1063). At 3 months, the cumulative incidence of infant infections was 13.6% in the azithromycin group compared with 17.3% in the placebo group (risk ratio (RR) 0.79; 95% CI 0.63 to 0.99; p=0.038). Infections among birthing parents, including SSTIs, were reduced with the greatest effect 1 week postdelivery (infections: RR 0.31; 95% CI 0.13 to 0.71; p=0.006, SSTIs: RR 0.25; 95% CI 0.08 to 0.75; p=0.013) but with a diminishing effect up to 6 months postdelivery. There was no effect on the prescription of antibiotics at any time point.

Intrapartum azithromycin prevents a variety of infections for birthing parents and infants up to 12 months post partum in Fiji. However, further research is required to identify target populations and better characterise potential impacts on antimicrobial resistance and the infant microbiome and resistome.

NCT03925480.

## Linked entities

- **Chemicals:** azithromycin (PubChem CID 447043)

## Full-text entities

- **Diseases:** AMR (MESH:D060467), scabies (MESH:D012532), COVID-19 (MESH:D000086382), diabetes (MESH:D003920), Infections (MESH:D007239), preterm onset of labour (MESH:D047928), meningitis (MESH:D008580), urinary tract infection (MESH:D014552), prolonged rupture of membranes (MESH:D005322), AE (MESH:D064420), wound infection (MESH:D014946), otitis (MESH:D010031), abscess (MESH:D000038), respiratory tract infection (MESH:D012141), SSTIs (MESH:D018461), conjunctivitis (MESH:D003231), neonatal death (MESH:D066087), abdominal or pelvic abscess (MESH:D018784), malnutrition (MESH:D044342), Staphylococcal scaled skin syndrome (MESH:D013207), death (MESH:D003643), pyelonephritis (MESH:D011704), maternal (MESH:D000079262), fever (MESH:D005334), GBS (MESH:D003057), endometritis (MESH:D004716), chorioamnionitis (MESH:D002821), staphylococcal scalded skin syndrome (MESH:D013206), Childhood Illness (MESH:D062027), malaria (MESH:D008288), cardiac, renal or hepatic abnormalities (MESH:D066126), hearing impairment (MESH:D034381), infectious diseases (MESH:D003141), invasive disease (MESH:D009361), tears (MESH:D012167), bloodstream infections (MESH:D018805), mastitis (MESH:D008413), skin and other infection (MESH:D012878), neonatal (MESH:D007232), Bacterial infection (MESH:D001424), stillbirth (MESH:D050497), neonatal sepsis (MESH:D000071074), cellulitis (MESH:D002481), underweight (MESH:D013851), pneumonia (MESH:D011014), prematurity (MESH:C536271), postpartum (MESH:D006473), diarrhoea (MESH:D003967), ophthalmia neonatorum (MESH:D009878), maternal death (MESH:D063130), wasting (MESH:D019282), postoperative wound infection (MESH:D013530)
- **Chemicals:** macrolide (MESH:D018942), Azithromycin (MESH:D017963), AZI (-), benzylpenicillin (MESH:D010400)
- **Species:** Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Staphylococcus aureus (species) [taxon 1280], Homo sapiens (human, species) [taxon 9606], Klebsiella pneumoniae (species) [taxon 573], Streptococcus sp. 'group B' (species) [taxon 1319], Neisseria meningitidis (species) [taxon 487], Escherichia coli (E. coli, species) [taxon 562], Streptococcus pneumoniae (species) [taxon 1313], Streptococcus pyogenes (species) [taxon 1314], Chlamydia trachomatis (species) [taxon 813], Mucilaginibacter sp. Hn (species) [taxon 1300009], Neisseria gonorrhoeae (species) [taxon 485]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12970096/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12970096/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12970096/full.md

---
Source: https://tomesphere.com/paper/PMC12970096